Efficacy analysis of ibuprofen combined with loratadine in the treatment of children with systemic inflammatory response syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053237

Enrollment

Unknown

Registered

2021-11-17

Start date

2021-11-15

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic inflammatory response syndrome in children

Interventions

Group 1:Ibuprofen combined with loratadine therapy

Group 2:Ibuprofen

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children who meet the diagnostic criteria of systemic inflammatory response syndrome admitted to the PICU ward of Hu'nan Children's Hospital, aged 28 days to 18 years. 2. The collection of blood samples and clinical information was obtained with the informed consent of their guardians and the signing of the ''Informed Consent'', which was approved by the ethics committee.

Exclusion criteria

Exclusion criteria: Diagnosed with lymphoma, HIV, immunodeficiency.

Design outcomes

Primary

Measure	Time frame
Procalcitonin;C-reactive protein;	—

Countries

China

Contacts

Public ContactLu Xiulan

Hu'nan Children's Hospital

391118947@qq.com+86 13787252674

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026